Wandena S. Siegel-Lakhai
The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital
Amsterdam
Name/email consistency: medium
- Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Siegel-Lakhai, W.S., Beijnen, J.H., Schellens, J.H. Oncologist (2005)
- Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Siegel-Lakhai, W.S., Crul, M., Zhang, S., Sparidans, R.W., Pluim, D., Howes, A., Solanki, B., Beijnen, J.H., Schellens, J.H. Br. J. Cancer (2005)